Application of salidroside in preparing medicine for treating duchenne muscular dystrophy

A technology of Duchenne muscular nutrition and salidroside, which is applied in drug combinations, pharmaceutical formulas, muscular system diseases, etc., and can solve problems such as no salidroside

Inactive Publication Date: 2014-11-19
SCI RES TRAINING CENT FOR CHINESE ASTRONAUTS
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, there is no report on the role of salidroside as an effective active ingredient in the treatment of genetic diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of salidroside in preparing medicine for treating duchenne muscular dystrophy
  • Application of salidroside in preparing medicine for treating duchenne muscular dystrophy
  • Application of salidroside in preparing medicine for treating duchenne muscular dystrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0037] The sources of experimental animals and materials used in the following experiments are as follows:

[0038] Experimental animals: female mdx and its normal wild-type control C57BL / 10 mice were purchased from the Institute of Model Animals, Nanjing University, production license number: SCXK (Su) 2010-0001. mdx is a dystrophin gene knockout mouse, which is currently internationally recognized and the most widely used animal model for studying human Duchenne muscular dystrophy.

[0039] Grouping and administration of experimental animals:

[0040]In the following six experiments, the experimental animals of each experiment were divided into three groups, 6 in each group:

[0041] Salidroside treatment group: mdx mice were given 28 days of continuous intragastric administration, with a dose of salidroside 50 mg / d / kg;

[0042] PBS control treatment group: mdx mice were continuously gavaged with equal volume solvent PBS every day for 28 days;

[0043] Normal control grou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of salidroside in preparing medicine for treating duchenne muscular dystrophy. According to the invention, experimental results show that salidroside can restrain skeletal muscle myolemma from rupture and necrosis, alleviate inflammatory reaction and fibrosis of skeletal muscles and enhance kinetism of skeletal muscles during the animal model paroxysm process of duchenne muscular dystrophy so as to express the function for treating duchenne muscular dystrophy.

Description

Technical field: [0001] The invention relates to a new application of the compound salidroside, in particular to the application of the salidroside in the preparation of drugs for treating Duchenne muscular dystrophy. Background technique: [0002] Duchenne muscular dystrophy (DMD) is a severe clinical fatal genetic disease caused by the deletion of the dystrophin gene located on the human X chromosome. Patients will show obvious muscle weakness when they are about 5 years old, and they can only use wheelchairs when they are 10-12 years old. Between 17-30 years old, they often cause respiratory failure caused by large-scale necrosis and fibrosis of the diaphragm. die. On average, there is one child with Duchenne muscular dystrophy in every 3,500 newborn male babies in the world, and the number of patients is several million. In my country, the number of patients currently exceeds 100,000. [0003] The pathogenesis of Duchenne muscular dystrophy is related to the function o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7032A61P21/00
Inventor 陈晓萍张鹏刘红菊
Owner SCI RES TRAINING CENT FOR CHINESE ASTRONAUTS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap